Brain Cancer Clinical Trials in North Carolina

Showing 81-93 of 93 trials

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

NCT00979862

This phase I trial is studying the side effects and best dose of cediranib maleate when given together with cilengitide in treating patients with progressive or recurrent glioblastoma. Cediranib maleate and cilengitide may stop the growth of tumor cells by blocking blood flow to the tumor. Giving cediranib maleate together with cilengitide may kill more tumor cells.

Adult Giant Cell GlioblastomaAdult GlioblastomaAdult Gliosarcoma+1 more

National Cancer Institute (NCI)47 participantsStarted Mar 2010

Birmingham, Alabama, United States • Atlanta, Georgia, United States • Baltimore, Maryland, United States +8 more locations

COMPLETEDPHASE141 miles

Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

NCT00093613

This phase I trial is studying the side effects and best dose of sorafenib in treating patients with recurrent or progressive malignant glioma. Sorafenib may stop the growth of tumor cells by stopping blood flow to the tumor and by blocking the enzymes necessary for their growth.

Adult Anaplastic AstrocytomaAdult Anaplastic OligodendrogliomaAdult Giant Cell Glioblastoma+2 more

National Cancer Institute (NCI)47 participantsStarted Dec 2004

Birmingham, Alabama, United States • Tampa, Florida, United States • Atlanta, Georgia, United States +7 more locations

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

Brain Cancer Trials in Other Cities

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors

Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma

Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients

A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma

Other Conditions in North Carolina